|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1990-6-19
|
|
pubmed:abstractText |
Nine patients with progressive, metastatic disease from primary carcinoma of the colon were entered into a phase I/II study using continuous intravenous infusions of granulocyte-macrophage colony-stimulating factor (GM-CSF) and high dose melphalan (120 mg m-2). GM-CSF was given alone to six patients during the first part of the study to determine a dose that would produce a peripheral leucocyte count (WCC) greater than or equal to 50 X 10(9) 1(-1) and was initially given at 3 micrograms kg-1 day-1 and escalated to 10 micrograms kg-1 day-1 after 10 days. The infusion was discontinued when the WCC exceeded 50 X 10(9) 1(-1) and after a gap of one week, melphalan was given over 30 min. GM-CSF was recommenced 8 h later and was continued until the neutrophil count had exceeded 0.5 X 10(9) 1(-1) for greater than 1 week. One patient achieved a WCC greater than 50 X 10(9) 1(-1) with GM-CSF 3 micrograms kg-1 day-1, but the other five who entered this phase of the study required dose escalation to 10 micrograms kg-1. No toxicity attributed to GM-CSF was seen. After melphalan, the median times to severe neutropenia (less than 0.5 X 10(9) 1(-1] and thrombocytopenia (greater than 20 X 10(9) 1(-1] were 6 and 9 days respectively. The median durations of neutropenia and thrombocytopenia were 14 and 10 days respectively. All patients required intensive support with a median duration of inpatient stay of 24 days. There was one treatment related death due to renal failure. One complete and two partial remissions (33% response rate) were seen but these were of short duration (median of 10 weeks). This study demonstrates that GM-CSF given by continuous intravenous infusion produces significant increments of peripheral granulocyte counts at 3 and 10 micrograms kg-1 day-1 and is not associated with any toxicity. The duration of neutropenia and thrombocytopenia induced by high-dose melphalan appears to be reduced by the subsequent administration of GM-CSF to times which are at least as short as have been reported in historical series which have used autologous bone marrow rescue.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-2478178,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-263243,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-2644886,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-2667607,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-2829955,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-2895212,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-2990035,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-3045544,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-3047340,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-3281007,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-3282709,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-3500414,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-3512113,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-3516430,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-3525764,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-3534154,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-3593657,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-400698,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-6215979,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-6351883,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-6354413,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-6366139,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-6999898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-7037150,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-7432433,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1692472-858124
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
749-54
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:1692472-Adult,
pubmed-meshheading:1692472-Aged,
pubmed-meshheading:1692472-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1692472-Colonic Neoplasms,
pubmed-meshheading:1692472-Colony-Stimulating Factors,
pubmed-meshheading:1692472-Drug Evaluation,
pubmed-meshheading:1692472-Female,
pubmed-meshheading:1692472-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:1692472-Granulocytes,
pubmed-meshheading:1692472-Humans,
pubmed-meshheading:1692472-Male,
pubmed-meshheading:1692472-Melphalan,
pubmed-meshheading:1692472-Middle Aged,
pubmed-meshheading:1692472-Recombinant Proteins
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.
|
|
pubmed:affiliation |
CRC Dept of Medical Oncology, Christie Hospital, Manchester, UK.
|
|
pubmed:publicationType |
Journal Article
|
